Synergy of arbekacin-based combinations against vancomycin hetero-intermediate Staphylococcus aureus

This study was undertaken to evaluate the in vitro activities of arbekacin-based combination regimens against vancomycin hetero-intermediate Staphylococcus aureus (hetero-VISA). Combinations of arbekacin with vancomycin, rifampin, ampicillin-sulbactam, teicoplanin, or quinupristin-dalfopristin again...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Korean medical science 2006, 21(2), , pp.188-192
Main Authors: Lee, Ji Young, Oh, Won Sup, Ko, Kwan Soo, Heo, Sang Taek, Moon, Chi Sook, Ki, Hyun Kyun, Kiem, Sungmin, Peck, Kyong Ran, Song, Jae Hoon
Format: Article
Language:English
Subjects:
Aminoglycosides - administration & dosage
Ampicillin - administration & dosage
Anti-Bacterial Agents - administration & dosage
Dibekacin - administration & dosage
Dibekacin - analogs & derivatives
Drug Resistance, Bacterial
Drug Synergism
Humans
In Vitro Techniques
Methicillin Resistance
Microbial Sensitivity Tests
Original
Staphylococcal Infections - drug therapy
Staphylococcal Infections - microbiology
Staphylococcus aureus - drug effects
Staphylococcus aureus - isolation & purification
Sulbactam - administration & dosage
Teicoplanin - administration & dosage
Vancomycin - administration & dosage
Virginiamycin - administration & dosage
의학일반
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study was undertaken to evaluate the in vitro activities of arbekacin-based combination regimens against vancomycin hetero-intermediate Staphylococcus aureus (hetero-VISA). Combinations of arbekacin with vancomycin, rifampin, ampicillin-sulbactam, teicoplanin, or quinupristin-dalfopristin against seven hetero-VISA strains and two methicillin-resistant S. aureus strains were evaluated by the time-kill assay. The combinations of arbekacin with vancomycin, teicoplanin, or ampicillin-sulbactam showed the synergistic interaction against hetero-VISA strains. Data suggest that these arbekacin-based combination regimens may be useful candidates for treatment options of hetero-VISA infections.
ISSN:1011-8934
1598-6357
DOI:10.3346/jkms.2006.21.2.188